Journal of Clinical Oncology
Articles in this Issue
Neoadjuvant NASOX for pancreatic cancer: A prospective multicenter study.
e16446 Background: Neoadjuvant therapy has become standard practice for selected patients with pancreatic cancer, with pro...
Trends in mortality among older diabetic patients with lung cancer in the United States (1999–2023).
e20779 Background: Lung cancer is the leading cause of cancer death in the United States. Diabetes is common in older adul...
First-line (1L) cadonilimab plus AK117 and chemotherapy (chemo) in advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from a phase 2 study.
e16040 Background: Cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemo is approved in China for 1L treatment of...
A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
5014 Background: Prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1)...
Prevalence and factors associated with chemotherapy-induced anemia in early and locally advanced breast cancer: A prospective tertiary care center study from India.
e12688 Background: Chemotherapy-induced anemia (CIA) affects up to 89% of non-anemic cancer patients undergoing chemothera...
Comprehensive molecular profiling of salivary gland cancers: A single-institution experience.
e18136 Background: Standardized therapeutic strategies are currently lacking for salivary gland cancers (SGCs). Molecular...
Trends in eligibility criteria in solid tumor systemic therapy trials over time.
e23018 Background: Friends of Cancer Research (FRIENDS) advocates for the broadening of eligibility criteria to ensure cli...
Potential cancer susceptibility genes in metastatic lung cancer: A Hong Kong territory–wide genomic study.
e22646 Background: Cancer susceptibility genes (CSGs) are increasingly identified in lung cancer with the widespread adopt...
Adjuvant or rescue disitamab vedotin for high-risk non–muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.
4616 Background: Disitamab vedotin (DV), a HER2-targeted antibody–drug conjugate (ADC), has shown efficacy in metastatic u...
Epidemiological trends and burden of liver cancer mortality due to hepatitis B in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e16209 Background: Hepatitis B virus (HBV) remains a major driver of liver cancer mortality in South Asia. Despite the ava...
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.
3013 Background: B7-H4, a transmembrane glycoprotein, has limited expression in normal tissue, but is upregulated in a var...
Integrating tumor-infiltrating iymphocytes (TILs) in the biomarker landscape of gastroesophageal adenocarcinoma: Going beyond PD-L1.
4098 Background: Immune checkpoint inhibitors (CPI) are standard of care in perioperative and metastatic gastro-esophageal...
Older adults with extensive-stage small-cell lung cancer treated with first-line chemoimmunotherapy: Updated systematic review and meta-analysis.
e20152 Background: Small-cell lung cancer (SCLC) accounts for ~10–15% of lung cancers, and most patients present with exte...
Integrating tumor growth models to improve late-stage lung cancer outcome prediction using early-stage clinical trial data.
8532 Background: Immunotherapy has substantially improved clinical outcomes but poses distinct challenges for response ass...
Noninvasive detection of early gastric cancer via red blood cell DNA features associated with tumor-induced hematopoietic stress.
4093 Background: Early detection of gastric cancer (GC) is limited by invasive endoscopy and the low sensitivity of curren...
Survival outcomes of neoadjuvant endocrine therapy versus chemotherapy in hormone receptor–positive breast cancer: An NCDB analysis.
e12669 Background: Neoadjuvant endocrine therapy (NET) and neoadjuvant chemotherapy (NCT) are accepted treatment strategie...
Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
5069 Background: Inhibition of androgen receptor (AR)-signaling results in increases in double-strand DNA breaks and genom...
Cardiovascular safety planning in NCCN-cited breast cancer trials: Audit and surveillance framework.
e24022 Background: Cardiovascular (CV) and venous thromboembolism (VTE) risks differ across systemic breast cancer therapi...
Access to trastuzumab deruxtecan for HER2-low metastatic breast cancer in Brazil’s Unified Public Health System: A population-impact model.
1539 Background: HER2-low disease has recently emerged as a distinct, targetable category in metastatic breast cancer (MBC...
Breast cancer care in Armenia: An assessment of diagnostic and treatment capacity.
e13623 Background: Timely diagnosis and access to treatment are essential components of effective breast cancer care. Desp...
Strengthening supportive care–patient guidance oncology models for adolescents and young adults with cancer: A community-based approach by Gunvati Jagan Nath Kapoor Foundation GJK.
e23062 Background: Adolescents and Young Adults (AYA) with cancer face unique clinical, psychosocial, and socioeconomic ch...
Identification and frequency of <i>EGFR</i> mutations among NSCLC patients in Nigeria: Preliminary findings.
e20057 Background: Epidermal Growth Factor Receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), particularly a...
Impact of the Navya Earthshot–enabled clinical decision support system on treatment turnaround time in oncology care: A real-world study from a tertiary cancer center in India.
1588 Background: Delays in Oncology care often result from systemic inefficiencies and patient-related barriers, leading t...
The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).
6517 Background: Pts with R/R B-ALL and EMD have limited treatment options and are a population with an unmet need. Obe-ce...
Doubling cascade testing uptake for hereditary cancer syndromes: Results from a cluster randomized controlled trial of a registry-aided outreach approach.
11007 Background: Cascade genetic testing for at-risk relatives (ARR) is the most critical strategy for cancer prevention...